Celgene is one of the world's largest biotech companies, with annual sales of more than $5 billion. Its mission is to discover and develop treatments for cancer and other severe inflammatory conditions. To that end, Celgene’s most valuable asset is its intellectual property portfolio. Cozen O’Connor protects that portfolio by handling all of Celgene’s non-patent intellectual property work, including transactions, prosecutions, enforcement, and litigation. In June 2010, the firm supported Celgene in its $2.9-billion purchase of Abraxis BioScience, the developer of a new chemotherapy technology. Beyond any one deal, Celgene relies on Cozen O’Connor’s depth of knowledge about its trademark portfolio and its business to make smart decisions that will benefit the company in the long term. Celgene trusts Cozen O’Connor attorneys to find creative alternatives to court—and to act confidently when litigation is the best option.